People: Bioheart Inc (BHRT.PK)

BHRT.PK on OTC Markets Group

0.03USD
24 May 2013
Price Change (% chg)

$-0.00 (-6.06%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.04
Day's Low
$0.03
Volume
385,725
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

William Murphy

 88 2010 Chairman of the Board

Mike Tomas

 46 2010 President, Chief Executive Officer, Director

Kristin Comella

 34 2013 Chief Scientific Officer, Director

Samuel Ahn

 58 2010 Director

Mark Borman

 57 2010 Independent Director

Charles Hart

 51 2009 Independent Director

Jeanne Becker

 IR Contact Officer
» Insider Trading

Biographies

Name Description

William Murphy

 Dr. William P. Murphy, Jr., M.D., is Chairman of the Board of Bioheart, Inc. Dr. Murphy has served as a member of the Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida.

Mike Tomas

 Mr. Mike Tomas is President, Chief Executive Officer, Director of Bioheart, Inc. He was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s board as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was sold in 2001. Today Mr. Tomas sits on the boards of Perimeter Internetworking (SaaS providing secure transfer of information for medical and financial institutions), Avisena (revenue cycle management for medical practices) and Total Home Health (Medicare-certified home care provider). Mr. Tomas is also the current chairman of the Global Entrepreneurship Center at Florida International University and a founding coach/mentor at the University of Miami’s Launch Pad at the Toppel Center. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelors degree from Florida International University.

Kristin Comella

 Ms. Kristin C. Comella is Chief Scientific Officer, Director of Bioheart, Inc. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as the Vice President of R&D and Corporate Development since December 2008 and has played a role in managing the product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with an experience in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has over fifteen years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.

Samuel Ahn

 Dr. Samuel S. Ahn, M.D., is Director of Bioheart, Inc. Dr. Ahn previously served as a member of the Company's Board of Directors from January 2001 to September 2008. Dr Ahn was one of the early pioneers in developing the field of endovascular surgery by coordinating and the first endovascular training courses in the US and Europe as well as developing some of the endovascular devices and techniques currently in clinical use today. He is a former Professor of Surgery in the Division of Vascular Surgery at UCLA, where he was also the Director of the Endovascular Surgery Program. In 2006 Dr. Ahn founded Vascular Management Associates, Inc., a consulting and management firm that sets up outpatient endovascular centers across the US. In 2008, he co-founded Wright-Ahn Technology, LLC, to develop and commercialize endovascular devices. In 2009, he co-founded MediBank International, LLC, a global healthcare IT Company. Dr. Ahn graduated from the University of Texas, Southwestern Medical School in Dallas, and received his general and vascular surgical residency training at UCLA. He also earned his MBA from the UCLA Anderson School of Management in August, 2004. Dr. Ahn sits on five vascular journal editorial boards, and has published over 120 peer-reviewed manuscripts, 50 book chapters, and five textbooks, including the first and definitive textbook on Endovascular Surgery. During the past eighteen years he has consulted for over 50 biomedical companies, both new and established, and has authored over 15 patents.

Mark Borman

 Mr. Mark P. Borman is Independent Director of Bioheart, Inc. He is a seasoned financial officer with more than 30 years of broad-based financial and investor relations experience. Mr. Borman brings small-company entrepreneurial passion and larger-company disciplines. In addition to the experience he gained working with entrepreneurs and their startups from 2009 to present, Mr. Borman has experience with global, NASDAQ- and NYSE-listed companies in various executive and financial roles. He most recently served as Corporate Officer, Treasurer and Vice President of Investor Relations with ADC Telecommunications. During his career, Mr. Borman has held positions with General Instrument Corporation, First Chicago Corporation, FMC Corporation, Price Waterhouse, and KPMG. Mr. Borman received his B.A. in Accounting from Michigan State University and his M.B.A. from the University of Chicago Graduate School of Business. He is a Certified Public Accountant and Chartered Financial Analyst and has experience as an advisor, board member, faculty, speaker, and mentor.

Charles Hart

 Mr. Charles A. Hart serves as Independent Director of Bioheart, Inc. Mr. Hart has more than 20 years of entrepreneurial experience. Mr. Hart founded Hart Masonry, Inc. in 1986 and has served as its President since then. He is also the Founder and President of Wildridge Enterprises. Mr. Hart is a member of the Board of Directors for Eagle Street Properties LLP.

Jeanne Becker

Basic Compensation

Name Fiscal Year Total

William Murphy

 --

Mike Tomas

 270,599

Kristin Comella

 126,204

Samuel Ahn

 --

Mark Borman

 --

Charles Hart

 --

Jeanne Becker

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

William Murphy

 0 0

Mike Tomas

 0 0

Kristin Comella

 0 0

Samuel Ahn

 0 0

Mark Borman

 0 0

Charles Hart

 0 0

Jeanne Becker

 0 0

Insider Trading

Name Shares Traded Price

HART CHARLES A

 3,571,430 $0.01

AHN SAMUEL S

 5,500,000 $0.02

HART CHARLES A

 2,200,000 $0.03

AHN SAMUEL S

 1,084,200 $0.05

AHN SAMUEL S

 2,500,000 $0.04

MURPHY WILLIAM P JR

 1,666,670 $0.06
» Full list on Insider Trading
Search Stocks